Lipoprotein(a) and Atherosclerosis
Authors:
- Richard M. LawnRLRichard M. Lawn
- Kåre BergKBKåre Berg
- 1 August 1991
- journal article
- review article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 115 (3) , 209-218
Abstract
Lipoprotein(a) [Lp(a)], a lipoprotein variant, was relegated for almost 25 years to the study of a few specialists. During the past 3 to 4 years, however, there has been a tremendous upsurge of interest in Lp(a), primarily because of multidisciplinary efforts in structural and molecular biology. Findings emerging from these efforts include the following: Lp(a) represents a cholesteryl-ester, low-density-lipoprotein (LDL)-like particle with apolipoprotein (apo) B-100 linked to apo(a); apo(a) is a glycoprotein coded by a single gene locus on the long arm of chromosome 6, which has several alleles, accounting for its remarkable size polymorphism (300 to 800 kD); apo(a) size polymorphism relates to plasma levels and density distribution of Lp(a); apo(a) is strikingly similar to plasminogen; and in vitro, Lp(a), in appropriate levels, competes for some physiologic functions of plasminogen in the coagulation and fibrinolytic cascade and may thus be thrombogenic. The LDL-like properties of Lp(a) may also confer atherogenic potential, but the mechanisms underlying this atherogenicity remain to be defined. In epidemiologic studies, high plasma Lp(a) levels have been associated with an increased incidence of atherosclerotic cardiovascular disease, especially in patients less than 60 years of age. Moreover, Lp(a) has been found as an intact particle in the arterial intima, particularly in association with atherosclerotic plaque. This finding suggests that Lp(a) can transverse the endothelium, possibly by a non-receptor-mediated process, and, at the intimal level, acquire thrombogenic and atherogenic potentials. Current information justifies the need to determine plasma Lp(a) levels in patients with a history of atherosclerotic cardiovascular disease. Unfortunately, the available techniques need to be standardized. Apolipoprotein(a) exists in isoforms of different sizes, and the importance of determining apo(a) phenotypes in clinical practice remains to be established.Keywords
This publication has 55 references indexed in Scilit:
- A rapid increase in lipoprotein (a) levels after ethanol withdrawal in alcoholic menLife Sciences, 1991
- Lipoprotein (a). Heterogeneity and biological relevance.Journal of Clinical Investigation, 1990
- Relation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary Heart Disease in Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1990
- Apolipoprotein(a) size heterogeneity is related to variable number of repeat sequences in its mRNABiochemistry, 1990
- Genetic linkage between lipoprotein(a) phenotype and a DNA polymorphism in the plasminogen geneGenomics, 1988
- Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitorJournal of Molecular Medicine, 1988
- The genetic relationships between the kringle domains of human plasminogen, prothrombin, tissue plasminogen activator, urokinase, and coagulation factor XIIJournal of Molecular Evolution, 1987
- cDNA sequence of human apolipoprotein(a) is homologous to plasminogenNature, 1987
- Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modulesCell, 1985
- Lp(a) lipoprotein enters cultured fibroblasts independently of the plasma membrane low density lipoprotein receptorClinical Genetics, 1981